KINDSTAR GLOBALGENE TECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.6 HKD | +2.56% |
|
+3.90% | -4.76% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.76% | 195M | - | ||
| -17.39% | 8.25B | B+ | ||
| +39.20% | 3.58B | C+ | ||
| -39.11% | 2.46B | B- | ||
| -8.06% | 2.46B | - | ||
| -7.35% | 2.38B | B- | ||
| -19.01% | 1.55B | A- | ||
| -40.66% | 1.21B | C+ | ||
| +7.56% | 1.11B | B+ | ||
| -15.34% | 1.03B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 9960 Stock
- Ratings Kindstar Globalgene Technology, Inc.
